Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study

Fig. 1

Patient disposition through week 52. aPatients were screened between November 26, 2019 and May 20, 2021 for the SELECT-AXIS 2 master protocol, which used a common screening platform to assign patients to either the AS bDMARD-IR study or the nr-axSpA study. bPatients could have multiple criteria or multiple reasons for screening failure. cOther reasons included imaging, site, or system issues. dPatients did not fail screening. ePrimary reason for discontinuation provided. AS ankylosing spondylitis, bDMARD biologic disease-modifying antirheumatic drug, IR inadequate response, nr-axSpA non-radiographic axial spondyloarthritis

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us